Literature DB >> 17335679

Hepatic complications of hematopoietic cell transplantation.

Josh Levitsky1, Michael F Sorrell.   

Abstract

Acute and chronic liver disease contributes significantly to morbidity and mortality following hematopoietic cell transplantation (HCT). The best prognostic indicator for the development of severe liver dysfunction is an early rise in liver function test results after HCT. The leading causes soon after HCT are acute graft-versus-host disease (GVHD), sinusoidal obstruction syndrome, drug and total parenteral nutrition hepatotoxicity, sepsis, and viral infection. Hepatic herpesvirus and fungal infections after HCT, though uncommon, can be life-threatening and warrant immediate diagnosis and treatment. Hepatitis B, hepatitis C virus, iron overload, and chronic GVHD are among the most common causes for chronic liver disease after HCT. Because treatments are directed at the underlying etiology of liver disease, prompt diagnosis by means of laboratory tests, hepatic imaging, and often liver biopsy is required after HCT.

Entities:  

Mesh:

Year:  2007        PMID: 17335679     DOI: 10.1007/s11894-008-0022-y

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  43 in total

1.  Hepatitis G virus infection: clinical characteristics and response to interferon.

Authors:  P Karayiannis; S J Hadziyannis; J Kim; J M Pickering; M Piatak; G Hess; A Yun; M J McGarvey; J Wages; H C Thomas
Journal:  J Viral Hepat       Date:  1997-01       Impact factor: 3.728

2.  Sepsis-associated cholestasis.

Authors:  R H Moseley
Journal:  Gastroenterology       Date:  1997-01       Impact factor: 22.682

3.  Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease.

Authors:  Barbara C Gärtner; Hansjörg Schäfer; Katja Marggraff; Günter Eisele; Marco Schäfer; Dagmar Dilloo; Klaus Roemer; Hans-Jürgen Laws; Martina Sester; Urban Sester; Hermann Einsele; Nikolaus Mueller-Lantzsch
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

4.  High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation.

Authors:  George K K Lau; Yu-hung Leung; Daniel Y T Fong; Wing-yan Au; Yok-lam Kwong; Albert Lie; Ji-lin Hou; Yu-mei Wen; Amin Nanj; Raymond Liang
Journal:  Blood       Date:  2002-04-01       Impact factor: 22.113

5.  Veno-occlusive disease of the liver after blood and marrow transplantation: analysis of pre- and post-transplant risk factors associated with severity and results of therapy with tissue plasminogen activator.

Authors:  Mark R Litzow; Panagiotis D Repoussis; Georgene Schroeder; David Schembri-Wismayer; Kenneth P Batts; Peter M Anderson; Carola A S Arndt; Michael G Chen; Dennis A Gastineau; Morie A Gertz; David J Inwards; Martha Q Lacy; Ayalew Tefferi; Pierre Noël; Lawrence A Solberg; Louis Letendre; H Clark Hoagland
Journal:  Leuk Lymphoma       Date:  2002-11

6.  Transjugular liver biopsy in BMT.

Authors:  E Carreras; A Grañena; M Navasa; M Bruguera; V Marco; J Sierra; M D Tassies; J C García-Pagán; J M Martí; J Bosch
Journal:  Bone Marrow Transplant       Date:  1993-01       Impact factor: 5.483

7.  High-dose methylprednisolone treatment for acute graft-versus-host disease after bone marrow transplantation in adults.

Authors:  M D Kanojia; A A Anagnostou; A R Zander; L Vellekoop; G Spitzer; D S Verma; S Jagannath; K A Dicke
Journal:  Transplantation       Date:  1984-03       Impact factor: 4.939

8.  A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant.

Authors:  R A Bowden; S J Slichter; M Sayers; D Weisdorf; M Cays; G Schoch; M Banaji; R Haake; K Welk; L Fisher; J McCullough; W Miller
Journal:  Blood       Date:  1995-11-01       Impact factor: 22.113

9.  Hepatitis C virus infection and liver disease after allogeneic bone marrow transplantation.

Authors:  Y Fujii; K Kaku; M Tanaka; T Kaneko; N Matumoto; K Shinohara
Journal:  Bone Marrow Transplant       Date:  1994-05       Impact factor: 5.483

10.  Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation.

Authors:  George K K Lau; Ming-Liang He; Daniel Y T Fong; Angeline Bartholomeusz; Wing-Yan Au; Albert K W Lie; Stephen Locarnini; Raymond Liang
Journal:  Hepatology       Date:  2002-09       Impact factor: 17.425

View more
  5 in total

Review 1.  Diagnosis and differential diagnosis of hepatic graft versus host disease (GVHD).

Authors:  Karen E Matsukuma; Dongguang Wei; Kai Sun; Rajendra Ramsamooj; Mingyi Chen
Journal:  J Gastrointest Oncol       Date:  2016-04

2.  Drug-induced liver injury after allogeneic bone marrow transplantation.

Authors:  Takayoshi Tachibana; Akito Nozaki; Makiko Enaka; Eri Yamamoto; Rika Kawasaki; Hideyuki Koharazawa; Maki Hagihara; Daisuke Ishibashi; Yuki Nakajima; Hideyuki Kuwabara; Naoto Tomita; Yoshiaki Ishigatsubo; Shin Fujisawa
Journal:  Int J Hematol       Date:  2013-09-15       Impact factor: 2.490

3.  Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma.

Authors:  Brandon M Barney; Kenneth R Olivier; Robert C Miller; Michael G Haddock
Journal:  Radiat Oncol       Date:  2012-05-03       Impact factor: 3.481

4.  Abnormal liver tests are not sufficient for diagnosis of hepatic graft-versus-host disease in critically ill patients.

Authors:  Alexander H Yang; Mai Ai Thanda Han; Niharika Samala; Bisharah S Rizvi; Rachel Marchalik; Ohad Etzion; Elizabeth C Wright; Ruchi Patel; Vinshi Khan; Devika Kapuria; Vikramaditya Samala Venkat; David E Kleiner; Christopher Koh; Jennifer A Kanakry; Christopher G Kanakry; Steven Pavletic; Kirsten M Williams; Theo Heller
Journal:  Hepatol Commun       Date:  2022-05-09

5.  Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX.

Authors:  Mi-Jung Kim; Sae-Won Han; Dae-Won Lee; Yongjun Cha; Kyung-Hun Lee; Tae-Yong Kim; Do-Youn Oh; Se Hyung Kim; Seock-Ah Im; Yung-Jue Bang; Tae-You Kim
Journal:  Cancer Res Treat       Date:  2016-01-14       Impact factor: 4.679

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.